The Risk of Sulfasalazine‐ and Mesalazine‐Associated Blood Disorders
- 4 March 1995
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 15 (2) , 176-181
- https://doi.org/10.1002/j.1875-9114.1995.tb04352.x
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Antilymphocyte globulin for mesalazine-associated aplastic anaemiaThe Lancet, 1994
- Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugsBMJ, 1994
- Further validation of information recorded on a general practitioner based computerized data resource in the united kingdomPharmacoepidemiology and Drug Safety, 1992
- Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.BMJ, 1991
- Drug induced agranulocytosis peripheral destruction of polymorphonuclear Leukocytes and their marrow precursors☆Blood Reviews, 1990
- Immune‐mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodiesBritish Journal of Haematology, 1989
- SULPHASALAZINE IN RHEUMATOID ARTHRITIS: HAEMATOLOGICAL PROBLEMS AND CHANGES IN HAEMATOLOGICAL INDICES ASSOCIATED WITH THERAPYRheumatology, 1989
- Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.BMJ, 1986
- SULPHASALAZINE IN RHEUMATOID ARTHRITISThe Lancet, 1985